11C-PiB PET assessment of change in fibrillar amyloid-beta load in patients with Alzheimer's disease treated with bapineuzumab: a phase 2, double-blind, placebo-controlled, ascending-dose study - PubMed (original) (raw)
Clinical Trial
doi: 10.1016/S1474-4422(10)70043-0. Epub 2010 Feb 26.
David J Brooks, Martin N Rossor, Nick C Fox, Roger Bullock, William E Klunk, Chester A Mathis, Kaj Blennow, Jerome Barakos, Aren A Okello, Sofia Rodriguez Martinez de Liano, Enchi Liu, Martin Koller, Keith M Gregg, Dale Schenk, Ronald Black, Michael Grundman
Affiliations
- PMID: 20189881
- DOI: 10.1016/S1474-4422(10)70043-0
Clinical Trial
11C-PiB PET assessment of change in fibrillar amyloid-beta load in patients with Alzheimer's disease treated with bapineuzumab: a phase 2, double-blind, placebo-controlled, ascending-dose study
Juha O Rinne et al. Lancet Neurol. 2010 Apr.
Abstract
Background: Carbon-11-labelled Pittsburgh compound B ((11)C-PiB) PET is a marker of cortical fibrillar amyloid-beta load in vivo. We used (11)C-PiB PET to investigate whether bapineuzumab, a humanised anti-amyloid-beta monoclonal antibody, would reduce cortical fibrillar amyloid-beta load in patients with Alzheimer's disease.
Methods: Patients with mild-to-moderate Alzheimer's disease were randomly assigned to receive intravenous bapineuzumab or placebo in a ratio of seven to three in three ascending dose groups (0.5, 1.0, or 2.0 mg/kg). Each dose group was enrolled after safety review of the previous group. Randomisation was by interactive voice response system; masking was achieved with numbered kit allocation. Patients, investigators, study site personnel, sponsor staff, and carers were masked to treatment. Patients received up to six infusions, 13 weeks apart, and had (11)C-PiB PET scans at baseline and at weeks 20, 45, and 78. The primary outcome was the difference between the pooled bapineuzumab group and the pooled placebo group in mean change from screening to week 78 in (11)C-PiB cortical to cerebellar retention ratio averaged across six cortical regions of interest. Analysis was by modified intention to treat. This study is registered with EudraCT, number 2004-004120-12; ISRCTN17517446.
Findings: 28 patients were assigned to bapineuzumab (n=20) or placebo (n=8). 19 patients in the bapineuzumab group and seven in the placebo group were included in the modified intention-to-treat analysis. Estimated mean (11)C-PiB retention ratio change from baseline to week 78 was -0.09 (95% CI -0.16 to -0.02; p=0.014) in the bapineuzumab group and 0.15 (95% CI 0.02 to 0.28; p=0.022) in the placebo group. Estimated mean difference in (11)C-PiB retention ratio change from baseline to week 78 between the bapineuzumab group and the placebo group was -0.24 (95% CI -0.39 to -0.09; p=0.003). Differences between the bapineuzumab group and the placebo group in the individual regions of interest were similar to the overall mean difference. Adverse events were typically mild to moderate in severity and transient. Two patients in the 2.0 mg/kg bapineuzumab group had transient cerebral vasogenic oedema.
Interpretation: Treatment with bapineuzumab for 78 weeks reduced cortical (11)C-PiB retention compared with both baseline and placebo. (11)C-PiB PET seems to be useful in assessing the effects of potential Alzheimer's disease treatments on cortical fibrillar amyloid-beta load in vivo.
Funding: Elan Pharmaceuticals and Wyeth Research.
2010 Elsevier Ltd. All rights reserved.
Comment in
- Testing the amyloid hypothesis of Alzheimer's disease in vivo.
Gandy S. Gandy S. Lancet Neurol. 2010 Apr;9(4):333-5. doi: 10.1016/S1474-4422(10)70055-7. Epub 2010 Feb 26. Lancet Neurol. 2010. PMID: 20189880 Free PMC article. No abstract available.
Similar articles
- Amyloid-β 11C-PiB-PET imaging results from 2 randomized bapineuzumab phase 3 AD trials.
Liu E, Schmidt ME, Margolin R, Sperling R, Koeppe R, Mason NS, Klunk WE, Mathis CA, Salloway S, Fox NC, Hill DL, Les AS, Collins P, Gregg KM, Di J, Lu Y, Tudor IC, Wyman BT, Booth K, Broome S, Yuen E, Grundman M, Brashear HR; Bapineuzumab 301 and 302 Clinical Trial Investigators. Liu E, et al. Neurology. 2015 Aug 25;85(8):692-700. doi: 10.1212/WNL.0000000000001877. Epub 2015 Jul 24. Neurology. 2015. PMID: 26208959 Free PMC article. Clinical Trial. - Two phase 3 trials of bapineuzumab in mild-to-moderate Alzheimer's disease.
Salloway S, Sperling R, Fox NC, Blennow K, Klunk W, Raskind M, Sabbagh M, Honig LS, Porsteinsson AP, Ferris S, Reichert M, Ketter N, Nejadnik B, Guenzler V, Miloslavsky M, Wang D, Lu Y, Lull J, Tudor IC, Liu E, Grundman M, Yuen E, Black R, Brashear HR; Bapineuzumab 301 and 302 Clinical Trial Investigators. Salloway S, et al. N Engl J Med. 2014 Jan 23;370(4):322-33. doi: 10.1056/NEJMoa1304839. N Engl J Med. 2014. PMID: 24450891 Free PMC article. Clinical Trial. - Biomarker Exposure-Response Analysis in Mild-To-Moderate Alzheimer's Disease Trials of Bapineuzumab.
Russu A, Samtani MN, Xu S, Adedokun OJ, Lu M, Ito K, Corrigan B, Raje S, Liu E, Brashear HR, Styren S, Hu C. Russu A, et al. J Alzheimers Dis. 2016 May 3;53(2):535-46. doi: 10.3233/JAD-151065. J Alzheimers Dis. 2016. PMID: 27163805 Clinical Trial. - Positron emission tomography radiopharmaceuticals for imaging brain Beta-amyloid.
Vallabhajosula S. Vallabhajosula S. Semin Nucl Med. 2011 Jul;41(4):283-99. doi: 10.1053/j.semnuclmed.2011.02.005. Semin Nucl Med. 2011. PMID: 21624562 Review. - Bapineuzumab.
Kerchner GA, Boxer AL. Kerchner GA, et al. Expert Opin Biol Ther. 2010 Jul;10(7):1121-30. doi: 10.1517/14712598.2010.493872. Expert Opin Biol Ther. 2010. PMID: 20497044 Free PMC article. Review.
Cited by
- Amyloid-beta antibody binding to cerebral amyloid angiopathy fibrils and risk for amyloid-related imaging abnormalities.
Söderberg L, Johannesson M, Gkanatsiou E, Nygren P, Fritz N, Zachrisson O, Rachalski A, Svensson AS, Button E, Dentoni G, Osswald G, Lannfelt L, Möller C. Söderberg L, et al. Sci Rep. 2024 May 13;14(1):10868. doi: 10.1038/s41598-024-61691-2. Sci Rep. 2024. PMID: 38740836 Free PMC article. - A light at the end of the tunnel - from mutation identification to a potential treatment for Alzheimer's disease.
Lannfelt L. Lannfelt L. Ups J Med Sci. 2023 Nov 28;128. doi: 10.48101/ujms.v128.10316. eCollection 2023. Ups J Med Sci. 2023. PMID: 38084203 Free PMC article. Review. - Anti-Amyloid Monoclonal Antibodies for the Treatment of Alzheimer's Disease.
Cummings J, Osse AML, Cammann D, Powell J, Chen J. Cummings J, et al. BioDrugs. 2024 Jan;38(1):5-22. doi: 10.1007/s40259-023-00633-2. Epub 2023 Nov 13. BioDrugs. 2024. PMID: 37955845 Free PMC article. Review. - Inflammation, Autoimmunity and Neurodegenerative Diseases, Therapeutics and Beyond.
Garmendia JV, De Sanctis CV, Das V, Annadurai N, Hajduch M, De Sanctis JB. Garmendia JV, et al. Curr Neuropharmacol. 2024;22(6):1080-1109. doi: 10.2174/1570159X22666231017141636. Curr Neuropharmacol. 2024. PMID: 37898823 Free PMC article. - Human 8-cell embryos enable efficient induction of disease-preventive mutations without off-target effect by cytosine base editor.
Wei Y, Zhang M, Hu J, Zhou Y, Xue M, Yin J, Liu Y, Feng H, Zhou L, Li Z, Wang D, Zhang Z, Zhou Y, Liu H, Yao N, Zuo E, Hu J, Du Y, Li W, Xu C, Yang H. Wei Y, et al. Protein Cell. 2023 Jun 7;14(6):416-432. doi: 10.1093/procel/pwac043. Protein Cell. 2023. PMID: 37285261 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical